{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:10:50Z","timestamp":1789150250179,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"DOI":"10.1007\/s12072-026-11146-9","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:47:33Z","timestamp":1789148853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antiviral therapies are associated with reduced mortality but under-utilized in patients with viral hepatocellular carcinoma: a multinational REAL-HCC study"],"prefix":"10.1007","author":[{"given":"Taotao","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Chien","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Lun","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Won","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Chun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Yen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee-Fu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne Kimiko","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hao","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Vutien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huy","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Uojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramsey","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6275-4989","authenticated-orcid":false,"given":"Mindie H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"issue":"3","key":"11146_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2022;74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"11146_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jhep.2024.10.031","volume":"82","author":"EY Tan","year":"2021","unstructured":"Tan EY, Danpanichkul P, Yong JN, et al. Liver cancer in 2021: Global Burden of Disease study. J Hepatol. 2021;82(5):851\u2013860","journal-title":"J Hepatol"},{"issue":"4","key":"11146_CR3","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u20131599","journal-title":"Hepatology"},{"key":"11146_CR4","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 67(2):370\u2013398."},{"key":"11146_CR5","doi-asserted-by":"publisher","unstructured":"Bhattacharya D, Aronsohn A, Price J, Re L V, Panel A-IHG (2023). Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciad319","DOI":"10.1093\/cid\/ciad319"},{"key":"11146_CR6","unstructured":"European Association for the Study of the Liver. Electronic address eee, Clinical Practice Guidelines Panel C, representative EGB, Panel m (2020). EASL recommendations on treatment of hepatitis C: Final update of the series(\u2606). J Hepatol. ;73(5):1170\u20131218."},{"issue":"1","key":"11146_CR7","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/hepr.12584","volume":"46","author":"GM Liu","year":"2016","unstructured":"Liu GM, Huang XY, Shen SL, Hu WJ, Peng BG. Adjuvant antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis. Hepatol Res. 2016;46(1):100\u2013110","journal-title":"Hepatol Res"},{"issue":"7","key":"11146_CR8","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/apt.13548","volume":"43","author":"GL Wong","year":"2016","unstructured":"Wong GL, Tse YK, Chan HL, Yip TC, Tsoi KK, Wong VW. Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther. 2016;43(7):802\u2013813","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"11146_CR9","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1053\/j.gastro.2019.07.040","volume":"157","author":"AG Singal","year":"2019","unstructured":"Singal AG, Rich NE, Mehta N, et al. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology. 2019;157(5):1253-1263.e1252","journal-title":"Gastroenterology"},{"issue":"3","key":"11146_CR10","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3350\/cmh.2024.1015","volume":"31","author":"SW Lee","year":"2025","unstructured":"Lee SW, Yang SS, Tsai PC, et al. Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: a nationwide cohort study. Clin Mol Hepatol. 2025;31(3):899\u2013913","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"11146_CR11","first-page":"293","volume":"33","author":"FH Lui","year":"2020","unstructured":"Lui FH, Moosvi Z, Patel A, et al. Decreased risk of hepatocellular carcinoma recurrence with direct-acting antivirals compared with no treatment for hepatitis C: a meta-analysis. Ann Gastroenterol. 2020;33(3):293\u2013298","journal-title":"Ann Gastroenterol"},{"issue":"5","key":"11146_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.109621","volume":"51","author":"J Liu","year":"2025","unstructured":"Liu J, Bai S, Shi X, et al. Benefits of entecavir therapy in HBV-related hepatocellular carcinoma patients with compensated cirrhosis after hepatectomy: A ten-year retrospective cohort study. Eur J Surg Oncol. 2025;51(5): 109621","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"11146_CR13","doi-asserted-by":"publisher","first-page":"JCO2300757","DOI":"10.1200\/JCO.23.00757","volume":"42","author":"DQ Huang","year":"2024","unstructured":"Huang DQ, Hoang JK, Kamal R, et al. Antiviral therapy utilization and 10-Year outcomes in resected hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma. J Clin Oncol. 2024;42(7):JCO2300757","journal-title":"J Clin Oncol"},{"issue":"1","key":"11146_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/apt.14801","volume":"48","author":"VL Chen","year":"2018","unstructured":"Chen VL, Yeh ML, Le AK, et al. Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience. Aliment Pharmacol Ther. 2018;48(1):44\u201354","journal-title":"Aliment Pharmacol Ther"},{"issue":"13","key":"11146_CR15","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1016\/j.cgh.2023.04.020","volume":"21","author":"S Kudaravalli","year":"2023","unstructured":"Kudaravalli S, Kam LY, Huang DQ, Cheung R, Nguyen MH. Utilization of antiviral therapy for patients with hepatitis B-related hepatocellular carcinoma: a nationwide real-world US study. Clin Gastroenterol Hepatol. 2023;21(13):3305-3313 e3304","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"11146_CR16","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/apt.17794","volume":"59","author":"LY Kam","year":"2024","unstructured":"Kam LY, Yeo YH, Ji F, Henry L, Cheung R, Nguyen MH. Treatment rates and factors associated with direct-acting antiviral therapy for insured patients with hepatitis C-related hepatocellular carcinoma - a real-world nationwide study. Aliment Pharmacol Ther. 2024;59(3):350\u2013360","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"11146_CR17","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1007\/s12072-023-10579-w","volume":"17","author":"Z He","year":"2023","unstructured":"He Z, Wang B, Wu X, et al. Recompensation in treatment-naive HBV-related decompensated cirrhosis: a 5-year multi-center observational study comparing patients with ascites and bleeding. Hepatol Int. 2023;17(6):1368\u20131377","journal-title":"Hepatol Int"},{"key":"11146_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.02.041","author":"Y Sanchez-Torrijos","year":"2025","unstructured":"Sanchez-Torrijos Y, Fernandez-Alvarez P, Rosales JM, et al. Prognostic implications of recompensation of decompensated cirrhosis after SVR in patients with hepatitis C. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.02.041","journal-title":"J Hepatol"},{"issue":"5","key":"11146_CR19","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.jhep.2021.01.046","volume":"74","author":"M Reig","year":"2021","unstructured":"Reig M, Cabibbo G. Antiviral therapy in the palliative setting of HCC (BCLC-B and -C). J Hepatol. 2021;74(5):1225\u20131233","journal-title":"J Hepatol"},{"key":"11146_CR20","doi-asserted-by":"publisher","first-page":"7075935","DOI":"10.1155\/2017\/7075935","volume":"2017","author":"L He","year":"2017","unstructured":"He L, Liu X, Zhao Y, et al. Efficacy of nucleot(s)ide analogs therapy in patients with unresectable HBV-related hepatocellular carcinoma: a systematic review and meta-analysis. Dis Markers. 2017;2017:7075935","journal-title":"Dis Markers"},{"issue":"1","key":"11146_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10694-9","volume":"23","author":"H Lu","year":"2023","unstructured":"Lu H, Zheng C, Xiong B, Xia X. TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma. BMC Cancer. 2023;23(1): 235","journal-title":"BMC Cancer"},{"key":"11146_CR22","unstructured":"European Association for the Study of the L. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2025."},{"key":"11146_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-026-11108-1","author":"H You","year":"2026","unstructured":"You H, Maiwall R, Chen J, et al. APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update. Hepatol Int. 2026. https:\/\/doi.org\/10.1007\/s12072-026-11108-1","journal-title":"Hepatol Int"},{"issue":"1","key":"11146_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jhep.2024.02.033","volume":"81","author":"S Kudaravalli","year":"2024","unstructured":"Kudaravalli S, Huang DQ, Yeh ML, et al. Sex and ethnic disparities in hepatitis B evaluation and treatment across the world. J Hepatol. 2024;81(1):33\u201341","journal-title":"J Hepatol"},{"issue":"12","key":"11146_CR25","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1016\/j.cgh.2019.02.005","volume":"17","author":"M Brahmania","year":"2019","unstructured":"Brahmania M, Lombardero M, Hansen BE, et al. Association between severe serum alanine aminotransferase flares and hepatitis B e antigen seroconversion and HBV DNA decrease in untreated patients with chronic HBV infection. Clin Gastroenterol Hepatol. 2019;17(12):2541-2551 e2542","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"11146_CR26","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1111\/liv.14469","volume":"40","author":"S Aleman","year":"2020","unstructured":"Aleman S, Soderholm J, Busch K, Kovamees J, Duberg AS. Frequent loss to follow-up after diagnosis of hepatitis C virus infection: a barrier towards the elimination of hepatitis C virus. Liver Int. 2020;40(8):1832\u20131840","journal-title":"Liver Int"},{"issue":"12","key":"11146_CR27","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41575-024-00967-4","volume":"21","author":"LY Mak","year":"2024","unstructured":"Mak LY, Liu K, Chirapongsathorn S, et al. Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions. Nat Rev Gastroenterol Hepatol. 2024;21(12):834\u2013851","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"11146_CR28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s12072-024-10744-9","volume":"19","author":"J Chen","year":"2025","unstructured":"Chen J, Jia J, Zhuang H, et al. Assessing pricing and affordability of HBV treatment in Asia-Pacific region: a barrier to elimination. Hepatol Int. 2025;19(2):349\u2013357","journal-title":"Hepatol Int"},{"key":"11146_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2025.101928","author":"L Yao","year":"2025","unstructured":"Yao L, Ying X, Malik G, et al. A global comparison of hepatitis B & C drug pricing. Ann Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.aohep.2025.101928","journal-title":"Ann Hepatol"},{"issue":"4","key":"11146_CR30","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/S2468-1253(23)00335-7","volume":"9","author":"AD Marshall","year":"2024","unstructured":"Marshall AD, Willing AR, Kairouz A, et al. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions. Lancet Gastroenterol Hepatol. 2024;9(4):366\u2013382","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11146-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11146-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11146-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:47:35Z","timestamp":1789148855000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-026-11146-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":30,"alternative-id":["11146"],"URL":"https:\/\/doi.org\/10.1007\/s12072-026-11146-9","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"26 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mindie H. Nguyen received research grants via Stanford University from Pfizer, Enanta, Astra Zeneca, GSK, Delfi, Innogen, Exact Science, CurveBio, Gilead, Vir Biotech, Helio Health, National Institute of Health, and personal fees from consulting\/advisory board from Exelixis, Gilead, GSK. Hidenori Toyoda: Speaker: AbbVie, Gilead Sciences, Kowa, Terumo,\u00a0Fujifilm WAKO, AstraZeneca, and Bayer. Yao-Chun Hsu: Research grant: Gilead Sciences; Consultation:\u00a0AusperBio, Gilead Sciences,\u00a0GSK,\u00a0and Sysmex; Speaker:\u00a0Abbvie, Bristol-Myers Squibb, Gilead Sciences, Grand Marquis IVD, Grifols, Harvester Trading Co, Merck Sharp & Dohme, and Roche. Jee-Fu Huang: Research Grant: Gilead, Bristol-Myer-Squibb; Consultant: Roche, Sysmex, Boehringer Ingelheim, and Aligos; Speaker: Abbvie, Gilead, Merck, Sysmex, and Novo Nordisk. Wan-Long Chuang: Member of Advisory Board: Gilead, AbbVie, Aligos, Barinthus, PharmaEssentia; Speaker: Gilead, AbbVie, BMS, Roche. Cheng-Hao Tseng: Speaker: Roche, Eisai, and AstraZeneca. Yu Jun Wong received research grants from Changi General Hospital, Medicine Academic Clinical Program SingHealth and Gilead (via Changi General Hospital, Singapore), and consulting\/advisory board from Ipsen, Abbvie and Ferrings. Masaru Enomoto: Speakers: Abbvie and Gilead. The other authors have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board at Stanford University, Stanford, California, USA.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}